MPG.eBooks - Search Results - "(past OR part)

Cover Image

1

Pharmacoeconomic review report (resubmission): Nusinersen (Spinraza) (Biogen Canada Inc.) : indication : treatment of patients with 5q spinal muscular atrophy

Published 2019

CADTH

“...; symptoms generally appear between six and 18 months after birth and most patients will survive past the age...”

Cover Image

2

Pharmacoeconomic review report (resubmission): Nusinersen (Spinraza) (Biogen Canada Inc.) : indication : treatment of patients with 5q spinal muscular atrophy

Published 2019

CADTH

“...; symptoms generally appear between six and 18 months after birth and most patients will survive past the age...”